SCHEMBL137377

SCHEMBL137377

c1cc2ncncc2cn1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 10/20 0.60
PIK3CD O00329 1/20 0.43
PIK3CA P42336 1/20 0.43
MKNK2 Q9HBH9 1/20 0.39
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HTT P42858 1/20 0.38
NCOA1 Q15788 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38
CSNK1D P48730 1/20 0.37
CSNK1E P49674 1/20 0.37
CLK1 P49759 1/20 0.37
DYRK1A Q13627 1/20 0.37
HSP90AA1 P07900 1/20 0.37
FGFR4 P22455 1/20 0.37
TDO2 P48775 1/20 0.36
PDGFRB P09619 1/20 0.35
PDGFRA P16234 1/20 0.35
RPS6KA5 O75582 1/20 0.35
RPS6KA4 O75676 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29409337 1.00 EGFR (0.60) EGFRPIK3CDPIK3CAMKNK2KDM4E
Hydrochloric Acid SCHEMBL31066682 0.98 EGFR (0.58) EGFRPIK3CDPIK3CAMKNK2KDM4E
Hydrochloric Acid SCHEMBL322987 0.98 EGFR (0.58) EGFRPIK3CDPIK3CAMKNK2KDM4E
SCHEMBL29409356 0.83 EGFR (0.58) EGFRPIK3CDPIK3CAMKNK2KDM4E
SCHEMBL88606 0.83 EGFR (0.58) EGFRPIK3CDPIK3CAMKNK2KDM4E
SCHEMBL29976830 0.82 EGFR (0.47) EGFRPIK3CDPIK3CAMKNK2KDM4E
Trifluoroacetic Acid SCHEMBL30391689 0.82 EGFR (0.43) EGFR
Trifluoroacetic Acid SCHEMBL29977443 0.82 EGFR (0.43) EGFR
Hydrochloric Acid SCHEMBL30749407 0.81 EGFR (0.56) EGFRPIK3CDPIK3CAMKNK2KDM4E
Hydrochloric Acid SCHEMBL30749417 0.81 EGFR (0.56) EGFRPIK3CDPIK3CAMKNK2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025076059-A1 ROCAGLATE DERIVATIVES AND USES THEREOF TRUSTEES OF BOSTON UNIVERSITY (US) 2025-04-10 WO claimed
US-12129381-B1 Single vessel solvent based method for making a Zn/Cu composite IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2024-10-29 US claimed
US-20240336778-A1 SINGLE VESSEL SOLVENT BASED METHOD FOR MAKING A ZN/CU COMPOSITE IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2024-10-10 US claimed
US-12031043-B2 Method for synthesizing a micro/nanosphere-containing composite IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2024-07-09 US claimed
US-20230203060-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2023-06-29 US claimed
EP-4159739-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2023-04-05 EP claimed
US-20230002617-A1 METHOD FOR SYNTHESIZING A MICRO/NANOSPHERE-CONTAINING COMPOSITE IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2023-01-05 US claimed
US-11485862-B2 Metallophthalocyanine-ZnO hollow nanospheres composite IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2022-11-01 US claimed
EP-3967687-A1 SUBSTITUTED PHENYLPROPENYLPYRIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Shanghai Haiyan Pharmaceutical Technology Co., Ltd (CN) 2022-03-16 EP claimed
WO-2021239058-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 劲方医药科技(上海)有限公司 2021-12-02 WO claimed
WO-2012101238-A1 NEW PYRIMIDO[5,4-D]PYRIMIDYLAMINO PHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-08-02 WO claimed
US-7935824-B2 Ethylenediamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-05-03 US claimed
EP-0244352-B1 Pyrido[4,3-d]pyrimidine derivatives NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) 1993-03-31 EP claimed
EP-0145337-B1 ELECTROCHROMIC DEVICES CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) 1990-08-08 EP claimed
US-4808618-A ANTIALLERGENS NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 1989-02-28 US claimed
EP-0096723-B1 BATTERIES FABRICATED WITH ELECTROACTIVE POLYMERS CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) 1988-08-10 EP claimed
EP-0244352-A2 Pyrido[4,3-d]pyrimidine derivatives NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) 1987-11-04 EP claimed
US-4613211-A REVERSE COLOR CHANGING POLYMER FILM AS DISPLAY ELECTRODE CHEVRON RESEARCH COMPANY (US) 1986-09-23 US claimed
US-4579679-A Electroactive polymers CHEVRON RESEARCH COMPANY (US) 1986-04-01 US claimed
EP-0145337-A2 Electrochromic devices CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) 1985-06-19 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203060-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF KRAS, NRAS, TP53 EGFR 88/4885PIK3CD 46/4885PIK3CA 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.